Periodic Reporting for period 1 - MechanoGPER (Development of GPER agonists as a novel therapeutic option for pancreatic cancer)

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is extremely aggressive and has very poor prognosis. It is characterised by a significant desmoplasia, immune-deficient response, and drug resistance. We discovered that targeting...